Archon is a biotechnology firm that promotes next-generation antibody treatments through AI and computational protein design.
Archon Biosciences has raised $20.0M in total funding. The most recent round was Seed. The last funding was announced in October 2024.
Archon Biosciences's investors include Madrona, Alexandria Venture Investments, Pack Ventures, DUMAC, Sahsen Ventures.
Archon Biosciences is headquartered in Washington, United States.
Archon is a biotechnology firm that promotes next-generation antibody treatments through AI and computational protein design.
Archon Biosciences is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Archon Biosciences — Funding & Investors." VCBacked, October 30, 2024, https://www.vcbacked.co/company/archon-biosciences. Accessed August 1, 2026.
VCBacked. (2024). Archon Biosciences — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/archon-biosciences
{{cite web |title=Archon Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/archon-biosciences |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated